Definitive Contract 75F40120C00201
Award Date
9/29/20
Potential Completion Date
5/31/23
Potential Value
$349K
Federal Agency
Food and Drug Administration
Awardee
University Of Connecticut
Ultimate Awardee
Secretary Of State Connecticut
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Time and Materials
Place of Performance
Storrs, CT 06269, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $219,991 cost-no-fee definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct research on the "Continuous Manufacturing of Liposomes: Materials Understanding and Process Control." The contract is part of the FDA's broader program on continuous manufacturing of liposomes, a type of drug delivery system. UConn, a leading public research institution, will leverage its expertise in materials science, engineering,...
This is a $1,530,889.00 definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct a research study titled "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". The contract has a performance period ending on September 21, 2027 and is a cost-type contract with no fee. UConn, a non-profit 1862 land-grant university, has...
The University of Connecticut (UConn) has been awarded a $1,103,886 firm-fixed-price definitive federal contract by the Food and Drug Administration (FDA) for research and development related to the impact of active pharmaceutical ingredients on in situ forming implants and understanding in vitro and in vivo performance differences. This contract, which has a completion date of September 29, 2026, was issued under the FDA's Broad Agency Announcement for research and development to support...
This is a $973,150.35 definitive, firm fixed price contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) for a study on the "Impact of Polymer Attributes on the Performance of In Situ Forming Implants." The contract has a completion date of September 9, 2023 and was awarded on March 6, 2020. UConn, a non-profit educational institution, will leverage its expertise in scientific research and specialized services to support this FDA study....
This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Connecticut for "Assessing Long-Acting Injectable Formulations Using In Vivo Imaging". The potential value of the contract is $1,131,742.00 and it has a completion date of September 29, 2024. The contract is not set aside for a specific business category. Under this contract, the University of Connecticut is conducting research and analysis on...
This is a $1,417,987.00 federal contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn). The contract is a Definitive Contract without a set-aside designation. The contract involves a comparative trial of different packaging components of an opioid packaging solution to evaluate their impact on opioid safety outcomes. UConn is working with Hartford Hospital and the UConn Health Center as subcontractors on this research project, which aims to identify...
The University of Connecticut (UConn) was awarded a $1,310,263 cost-no-fee definitive contract by the Food and Drug Administration (FDA) to enhance and validate in vitro-in vivo correlation (IVIVC) methods for long-acting injectable drug products to accelerate their generic development. The contract is part of the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various areas to modernize regulatory science and support...
This is a $432,990 firm fixed price contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to the University of Connecticut to develop a single-administration microneedle skin patch for novel vaccination technology. The contract supports the national interest in response to the coronavirus pandemic. The University of Connecticut is a public research institution that frequently conducts work for the federal government...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $994,647.76 Purchase Order contract to Diant Pharma Inc. for a Pilot-Scale Nanoparticle Continuous Manufacturing System. Performance will take place in Storrs, Connecticut under firm fixed pricing terms. The contract begins on May 17, 2022 and concludes on November 29, 2023. Diant Pharma Inc. will provide pilot-scale continuous manufacturing equipment and services for developing nanoparticle drug...
This federal contract award, with ID 75F40119C10152, was issued by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) for a project titled "The Feasibility and Effectiveness of an Opioid Package Prototype (OPP) to Impact Opioid Prescribing, Dispensing, and Patient Use Outcome." The $831,029.30 definitive contract has a completion date of April 4, 2025 and is a cost-type contract with no fee. The project aims to study the impact of various opioid packaging...